Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Filana Therapeutics Q3 2026 Results: Net Loss of $10.7M, Loss Narrows

Filana Therapeutics reported a net loss of $10.7 million for the third quarter of 2026, with a significant reduction in nine-month operating expenses compared to the prior year. The company received a Nasdaq deficiency notice regarding its share price but maintains a cash position of $78.2 million, which management believes is sufficient for at least the next 12 months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-10.7-10.8
EPS (diluted, $ a share)$-0.22$-0.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: FLNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Filana Therapeutics, Inc.: key numbers

Share price
$0.4809Close, Nov 17
Market cap
$24.2M
Shares outstanding
50.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Filana Therapeutics, Inc.

All →
8:18 AM ET 8-K
Leadership Change

Filana Therapeutics Leadership Change

Filana Therapeutics appointed Jill M. Quigley to its Board of Directors as a Class I director, effective November 8, 2026. Ms. Quigley brings over 20 years of biopharma leadership experience, including previous CEO and COO roles at Genuiti Therapeutics and Passage Bio. Her appointment is intended to support the company as it prepares for a Phase 2a clinical study of simufilam in TSC-related epilepsy.

8:11 AM ET 8-K
Financial Results

Filana Therapeutics Financial Results

Filana Therapeutics reported Q3 2026 financial results, including a net loss of $10.7 million and a cash balance of $47.0 million. The company announced that patient screening for its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2027 following the recent lifting of an FDA clinical hold.

“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027.”

Rick Barry, President and Chief Executive Officer
8:18 AM ET 8-K
Court & Legal Update

Filana Therapeutics Court & Legal Update

The U.S. Court of Appeals for the Fifth Circuit vacated a lower court's order that had granted class certification in a securities class action against Filana Therapeutics. The appellate court ruled that the district court misapplied legal standards regarding market efficiency and 'meme-stock' dynamics, remanding the case for further proceedings.

Counterparty
U.S. District Court for the Western District of Texas
7:57 AM ET Form 4
Insider Buying

Filana Therapeutics President & CEO Richard Barry Buys $278K of Stock

Richard Barry, President & CEO, bought 306,813 shares of Filana Therapeutics, Inc. at $0.9 to $0.92 a share (average $0.9065) in 2 transactions, worth $278K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 1,337,964 (+8.1%).

Value
$278K
Shares
306,813
Average price
$0.9065
Role
President & CEO
Holding change
+8.1%
Trade date
Sep 29, 2026 to Sep 30, 2026
4:04 PM ET Form 4
Insider Buying

Filana Therapeutics President & CEO Richard Barry Buys $78.2K of Stock

Richard Barry, President & CEO, bought 93,091 shares of Filana Therapeutics, Inc. at $0.84 a share, worth $78.2K in total on Sep 28, 2026. Shares held after the trade: 1,031,151 (+9.9%).

Value
$78.2K
Shares
93,091
Price
$0.8400
Role
President & CEO
Holding change
+9.9%
Trade date
Sep 28, 2026
8:01 AM ET 8-K
Business Update

Filana Therapeutics Business Update

The FDA has lifted a full clinical hold on Filana Therapeutics' IND application for simufilam, allowing the company to proceed with a Phase 2a proof-of-concept study in TSC-related epilepsy. The company expects to begin patient screening by Q1 2027 and has already completed trial-readiness activities including site identification and drug supply preparation.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.